Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the FDA. The agency also placed a clinical hold on trials involving the drug.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/ocaliva-primary-biliary-cholangitis-withdrawn-us-market-2025a1000o4y?src=rss
Author :
Publish date : 2025-09-11 18:59:00
Copyright for syndicated content belongs to the linked Source.